FREDUN share price, P/E, ROE & financials

As of 6 Nov 2026, Fredun Pharmaceuticals trades at 53.5× trailing earnings, above the industry P/E of 28.7×, and the shares are 12% below their 52-week high. Its ROCE of 24% is the highest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales and net profit grew 32% and 45% a year over 3 years. Its dividend yield is 0.1%, and debt is 0.76× equity. It is a small-cap company with a market cap of ₹2,516 Cr, ranked 55th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 2.5% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹1,504.50
Day high: ₹1,506.90
Day low: ₹1,422.40
Prev. close: ₹1,497.00
Volume: 1.3 L

Health check

2 good · 1 fair · 3 to check

ReturnsBehind
+2.5% over a year, better than 1 of 7 peers.
Price tagPricier
P/E 53.5 vs industry 28.7.
GrowthStrong
Sales +32.2%, profit +44.5% a year over 3 years.
ProfitabilityStrong
ROCE 24.5% vs peer median 17.9%.
Balance sheetFair
Debt 0.76× equity, interest covered 2.3×, Piotroski 6 of 9.
Red flags2 to check
P/E of 53.5 against an industry P/E of 28.7.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹2,516 Cr, #55 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Jun 2026: sales ₹866 Cr · profit ₹48 Cr

Market cap: ₹2,516 Cr; Small cap
P/E: 53.5; Industry 28.7
Price to book: 7.53; Peers 4.99
Dividend yield: 0.05%
ROE: 19.7%; Peers 14.7%
ROCE: 24.5%; Peers 17.9%
Debt to equity: 0.76; Debt ₹253 Cr
EPS (TTM): ₹27.53; Face value ₹10
OPM (TTM): 14.9%; Net margin 5.6%
Sales growth: +90.7%; Latest quarter vs a year ago
Profit growth: +94.1%; Latest quarter vs a year ago
Price to sales: 2.90; EV/EBITDA 21.2

Strengths

Return on equity of 19.7%.
Return on capital employed of 24.5%.
Quarterly profit up 94.1% on a year ago.
Quarterly sales up 90.7% on a year ago.

Risks to check

P/E of 53.5 against an industry P/E of 28.7.
Interest coverage of only 2.7×.

Derived automatically from reported figures. Not a recommendation.

About Fredun Pharmaceuticals

Fredun Pharmaceuticals Limited manufactures and sells pharmaceutical formulations, dietary/herbal supplements, nutraceuticals, animal healthcare products, cosmeceuticals, mobility and rehabilitation products, and other healthcare products in India, Africa, Southeast Asia, Commonwealth of Independent States countries, MENA region, and Latin America. The company offers allopathic formulations, including analgesics/NSAID, antacid/antiulcer, anthelmintic,…

Headquarters: Mumbai
Employees: 736
Sector: Healthcare
ISIN: INE194R01017
Website: fredungroup.com

Price range

52 weeks

₹1,195.20₹1,665.00

Today

₹1,422.40₹1,506.90

Avg volume (3M): 1 L
1-year return: plus 2.5%
From 52-week high: minus 11.6%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
FREDUNFredun Pharmaceuticals	1,472.60	minus 1.63%	2,516	53.5	7.53	24.5%	15.4%	14.9%	32.2%	44.5%	0.05%	plus 2.5%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
119	144	160	210	228
102	121	134	182	195
17	22.3	26.3	28.9	32.7
14.2%	15.6%	16.5%	13.7%	14.4%
6.5	7.7	10.5	14.5	8.6
1.4	1.9	1.8	3.2	3.6
9	12.7	14	11.2	20.6
25.2%	25.8%	25.2%	4.2%	36.1%
6.8	9.4	10.5	10.8	13.1
4.78	6.66	7.40	6.07	7.40

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +32.2%
Profit CAGR 3Y: +44.5%
ROE: 19.7%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
274	347	452	633
–	+26.3%	+30.3%	+40.2%
247	309	390	531
27.8	38	61.7	102
10.1%	11.0%	13.7%	16.2%
0	−0.2	−8.7	−9.2
7.6	12.5	20.4	37.5
2.8	3.8	5	8.2
0.1	−0	–	−0.6
17.5	21.5	27.5	47
38.3%	27.2%	28.2%	30.6%
10.8	15.6	19.7	32.6
–	+44.6%	+26.3%	+65.3%
7.64	11.11	–	–

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
4.5	4.7	4.7	5.5
91.8	117	137	276
86.5	106	168	242
74.4	80.6	178	118
257	308	487	642
40.2	48	62.1	134
1.6	1.9	2	7.9
0	0	2	13.2
3.4	2.1	5.2	64.9
212	256	416	423
257	308	487	642

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
−14.4	−0.4	−16.6	11.9
−9.4	−7.6	−6.4	−73.6
25.2	6	26.7	121
1.4	−2.1	3.7	59.8
−9.5	−7.6	−6.1	−73.6
−23.9	−8.1	−22.7	−61.7

Shareholding pattern

Source: NSE filings

NSE hasn’t returned a shareholding pattern for this company. Institutions hold about 0.0% (Yahoo estimate).

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you